Retatrutide (LY3437943) Mechanism of Action

Why does retatrutide target three receptors instead of one?

Each of the three receptors contributes a distinct arm to energy balance, and the design rationale is that engaging all three produces a broader metabolic profile than any single- or dual-receptor agonist. In the preclinical characterisation by Coskun and colleagues (Cell Metabolism, 2022), the molecule showed balanced glucagon- and GLP-1-receptor activity with comparatively more prominent GIP-receptor activity, and in obese animal models glucagon-receptor engagement added an energy-expenditure component layered on top of the appetite- and glucose-related effects driven by the GIP and GLP-1 arms.

The strategic logic follows a clear progression within the incretin class. Semaglutide established that GLP-1 receptor agonism alone produces meaningful metabolic effects. Tirzepatide demonstrated that adding the GIP axis changes the profile again. Retatrutide asks whether a third, mechanistically distinct pathway — one that acts on energy expenditure rather than on intake and glucose handling — can be layered on top without the arms working against each other. That question is precisely what the ongoing clinical programme is designed to answer, and it is not yet fully resolved.

It is worth being clear about what “balanced” means in this context. In vitro receptor potency is measured in cell-based assays and does not translate directly into the relative contribution each arm makes in a living system, where receptor distribution, expression density, and downstream signalling all intervene. A compound can be more potent at one receptor in a dish and still have its in vivo profile dominated by another.

What does each receptor arm contribute?

The three receptors are all class B G-protein-coupled receptors, but they sit on different tissues and serve different physiological roles. The table below summarises them; the sections that follow cover each in turn.

What does GLP-1 receptor agonism contribute?

GLP-1 is the most established incretin target and the best-characterised of the three. GLP-1 receptor agonism underlies the pharmacology of semaglutide and is associated with glucose-dependent insulin secretion — meaning insulin release is potentiated when glucose is elevated rather than driven unconditionally — along with appetite and satiety signalling and a slowed rate of gastric emptying. Because every compound in this class shares the GLP-1 arm, it functions as the common baseline against which the GIP and glucagon additions are assessed.

What does GIP receptor agonism contribute?

GIP is the second incretin axis, secreted by intestinal K-cells, and is studied for its roles in insulin secretion and in how adipose tissue handles lipids and stores energy. In the retatrutide binding profile this arm is comparatively prominent. GIP biology is considerably more contested in the literature than GLP-1 biology — there has been genuine scientific debate over whether GIP receptor agonism or antagonism is the more useful metabolic strategy, since both have shown effects in different experimental contexts. Hammoud and Drucker (Nature Reviews Endocrinology, 2023) is the standard review of the contrasting cardiometabolic actions of GIP and GLP-1 and is the best entry point to that debate.

Why add glucagon receptor agonism at all?

This is the distinguishing arm and the most common point of confusion. Adding glucagon-receptor agonism to an incretin agonist is sometimes described as a paradox, because glucagon classically raises blood glucose by driving hepatic glucose output — the opposite of what an incretin agonist is trying to achieve.

The design intent is that GCGR-driven increases in energy expenditure are offset by the glucose-lowering incretin arms, so the net metabolic direction is maintained while an additional energy-expenditure mechanism is recruited that neither semaglutide nor tirzepatide accesses. In other words, the glucagon arm is included despite its glycaemic effect, not because of it, and the incretin arms are what make its inclusion tractable. Whether that balance holds across the full range of physiological conditions in humans is one of the open questions addressed below.

What is retatrutide’s molecular structure?

Retatrutide is a synthetic peptide engineered from a GIP-based backbone with several non-coded residue substitutions and a C20 fatty-diacid side chain. Building from a GIP scaffold rather than a GLP-1 one is itself notable: the molecule is, in structural terms, a modified GIP analogue that has been given GLP-1 and glucagon receptor activity through targeted substitution, rather than a GLP-1 analogue extended outward.

The non-coded amino acid substitutions serve two purposes at once. They tune the relative activity at each of the three receptors, and they confer resistance to enzymatic degradation — particularly by dipeptidyl peptidase-4 (DPP-4), which rapidly inactivates native incretin hormones and is the reason endogenous GLP-1 has a half-life measured in minutes.

The C20 fatty-diacid moiety promotes reversible binding to serum albumin. An albumin-bound peptide is protected from renal clearance and acts as a slowly-released circulating reservoir, which extends the effective half-life from minutes to a duration that supports once-weekly dosing in the clinical programme. This is the same broad strategy used across the class, though the specific chemistry differs between compounds — a point covered further in the structural comparison with tirzepatide and semaglutide.

The molecular weight is approximately 4,731 Da. In a research context this figure is not trivia: it is the value that mass-spectrometry identity confirmation on a Certificate of Analysis should be consistent with, and a reported observed mass that does not correspond to the expected molecular weight is a direct indication that the material is not what the label claims.

How does the molecule stay in circulation long enough to work?

Receptor activity alone does not make a viable compound. Native incretin hormones are cleared from circulation within minutes — endogenous GLP-1 has a half-life on the order of a couple of minutes — because dipeptidyl peptidase-4 (DPP-4) cleaves them rapidly and the kidneys filter what remains. Any therapeutic or investigational compound built on incretin biology has to solve that problem before receptor selectivity matters at all.

Retatrutide addresses it on two fronts simultaneously. The non-coded amino acid substitutions in the backbone confer resistance to enzymatic degradation, removing the DPP-4 vulnerability that limits the native hormones. The C20 fatty-diacid side chain then addresses renal clearance by promoting reversible binding to serum albumin — the most abundant protein in plasma.

Albumin binding works as a depot mechanism rather than a simple shield. A peptide bound to albumin is too large a complex for efficient renal filtration and is protected from proteolysis, while the binding is reversible enough that free peptide is continuously released back into circulation as it is consumed. The bound fraction behaves as a slowly-draining reservoir, converting a half-life measured in minutes into one measured in days — which is what supports the once-weekly cadence used in the clinical programme.

This is a shared strategy rather than a unique one: semaglutide and tirzepatide use the same broad approach with differing fatty-acid chemistry. It is worth understanding because it explains an otherwise puzzling feature of this compound class — why molecules targeting fast-acting, meal-associated gut hormones are administered on a weekly rather than a daily or per-meal schedule.

How does retatrutide compare with other incretin agonists?

For a fuller side-by-side of structure, half-life, and development stage, see how retatrutide differs from tirzepatide and semaglutide.

What does the clinical literature report?

Reported strictly as published, attributed clinical findings — not as product claims. The development programme has produced four principal publications to date:

• Discovery and preclinical characterisation — Coskun et al., Cell Metabolism (2022), which established the receptor-binding profile and reported effects in rodent models.
• Phase 2, obesity — Jastreboff et al., New England Journal of Medicine (2023), a 338-participant randomised, double-blind, placebo-controlled trial reporting the compound’s metabolic effects over 48 weeks.
• Phase 2, type 2 diabetes — Rosenstock et al., The Lancet (2023), a randomised placebo- and active-controlled trial reporting glycaemic and body-weight outcomes.
• Phase 2a, MASLD — Sanyal et al., Nature Medicine (2024), reporting reductions in liver fat measured by MRI-PDFF in participants with metabolic-dysfunction-associated steatotic liver disease.

Phase 3 registrational trials are ongoing. Retatrutide remains investigational and is not approved for clinical use anywhere. A neutral summary of the reported trial figures is maintained separately in our overview of the published clinical trial evidence; those figures are findings in clinical study populations and are not claims about any product.

Why is a single peptide used instead of combining three drugs?

A reasonable question is why the three activities are engineered into one molecule rather than achieved by administering three separate agonists together. The answer is partly practical and partly pharmacological.

Practically, three separate peptides would each need their own half-life-extension chemistry, their own stability and formulation profile, and their own manufacturing and quality-control pathway. Combining them would mean managing three independent pharmacokinetic curves that drift out of alignment as each is cleared at its own rate — so the ratio of receptor activities a subject experiences would change continuously over the dosing interval.

A single molecule fixes that ratio by construction. Because all three activities are carried on one peptide with one clearance profile, the balance between GIP, GLP-1, and glucagon engagement stays constant as concentration falls. Given that the entire design rationale depends on the incretin arms offsetting the glucagon arm, holding that ratio steady is not a convenience — it is central to whether the mechanism behaves as intended.

The trade-off is that the ratio is also fixed at the design stage and cannot be tuned afterwards. Adjusting the balance between receptor arms means engineering a different molecule and taking it through development again — which is one reason the field is exploring several distinct receptor combinations in parallel rather than converging on a single architecture.

What is retatrutide’s regulatory status in the UK?

What remains unknown about retatrutide?

A research page is more useful when it names what is not yet settled. Several questions remain genuinely open:

• Relative contribution of each receptor arm. How much of the observed profile is attributable to GIP, GLP-1, and glucagon engagement individually is not resolved, and is difficult to dissect experimentally in humans.
• Glucagon-receptor engagement in humans. The offsetting mechanism described above is a design rationale supported by preclinical and early clinical data; its full characterisation across physiological states is ongoing.
• Long-term durability. Whether effects are maintained over multi-year horizons, and what the trajectory looks like after discontinuation, are not yet answered by the published record.
• Comparative positioning. There are no published head-to-head trials against tirzepatide or semaglutide, so cross-trial comparison is the only available approach — and cross-trial comparison is confounded by differing populations, designs, and endpoints.

Acknowledging this uncertainty is both accurate and, we think, the honest way to write about an investigational compound.

Frequently asked questions

References

Every DOI below has been checked against the source of record rather than reproduced from a secondary summary.

1. Coskun T, et al. LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: from discovery to clinical proof of concept. Cell Metab. 2022;34(9):1234–1247. doi:10.1016/j.cmet.2022.07.013
2. Rosenstock J, et al. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial. Lancet. 2023;402(10401):529–544. doi:10.1016/S0140-6736(23)01053-X
3. Jastreboff AM, et al. Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. N Engl J Med. 2023;389(6):514–526. doi:10.1056/NEJMoa2301972
4. Sanyal AJ, et al. Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial. Nat Med. 2024;30(7):2037–2048. doi:10.1038/s41591-024-03018-2
5. Hammoud R, Drucker DJ. Beyond the pancreas: contrasting cardiometabolic actions of GIP and GLP1. Nat Rev Endocrinol. 2023;19(4):201–216. doi:10.1038/s41574-022-00783-3